CA2340457A1 - 14400 receptor, a g-protein coupled receptor - Google Patents

Info

Publication number

CA2340457A1

CA2340457A1 CA002340457A CA2340457A CA2340457A1 CA 2340457 A1 CA2340457 A1 CA 2340457A1 CA 002340457 A CA002340457 A CA 002340457A CA 2340457 A CA2340457 A CA 2340457A CA 2340457 A1 CA2340457 A1 CA 2340457A1

Authority

CA

Canada

Prior art keywords

amino acid

receptor

nucleic acid

polypeptide

protein

Prior art date

1998-08-20

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 108020003175 receptors Proteins 0.000 title abstract description 386
• 102000005962 receptors Human genes 0.000 title abstract description 366
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 title abstract description 52
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 title abstract description 51
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 169
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 162
• 229920001184 polypeptide Polymers 0.000 claims abstract description 151
• 108091033319 polynucleotide Proteins 0.000 claims abstract description 97
• 102000040430 polynucleotide Human genes 0.000 claims abstract description 97
• 239000002157 polynucleotide Substances 0.000 claims abstract description 97
• 238000000034 method Methods 0.000 claims abstract description 95
• 210000004027 cell Anatomy 0.000 claims description 181
• 150000001413 amino acids Chemical class 0.000 claims description 148
• 108090000623 proteins and genes Proteins 0.000 claims description 130
• 150000007523 nucleic acids Chemical class 0.000 claims description 129
• 239000012634 fragment Substances 0.000 claims description 125
• 102000039446 nucleic acids Human genes 0.000 claims description 107
• 108020004707 nucleic acids Proteins 0.000 claims description 107
• 102000004169 proteins and genes Human genes 0.000 claims description 93
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 92
• 150000001875 compounds Chemical class 0.000 claims description 80
• 239000013598 vector Substances 0.000 claims description 65
• 208000035475 disorder Diseases 0.000 claims description 63
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 54
• 239000003446 ligand Substances 0.000 claims description 51
• 125000003729 nucleotide group Chemical group 0.000 claims description 44
• 239000002773 nucleotide Substances 0.000 claims description 43
• 210000001519 tissue Anatomy 0.000 claims description 38
• 239000002299 complementary DNA Substances 0.000 claims description 36
• 230000000694 effects Effects 0.000 claims description 32
• 108020004999 messenger RNA Proteins 0.000 claims description 27
• 239000003795 chemical substances by application Substances 0.000 claims description 26
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 23
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 15
• 239000003153 chemical reaction reagent Substances 0.000 claims description 14
• 238000004519 manufacturing process Methods 0.000 claims description 11
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 10
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 10
• 230000000295 complement effect Effects 0.000 claims description 8
• 206010061218 Inflammation Diseases 0.000 claims description 7
• 238000001514 detection method Methods 0.000 claims description 7
• 230000004054 inflammatory process Effects 0.000 claims description 7
• 108091034117 Oligonucleotide Proteins 0.000 claims description 6
• 206010043554 thrombocytopenia Diseases 0.000 claims description 5
• 210000002798 bone marrow cell Anatomy 0.000 claims 3
• 238000012258 culturing Methods 0.000 claims 1
• 238000011282 treatment Methods 0.000 abstract description 29
• 230000001404 mediated effect Effects 0.000 abstract description 12
• 238000003745 diagnosis Methods 0.000 abstract description 9
• 239000005557 antagonist Substances 0.000 abstract description 8
• 239000000556 agonist Substances 0.000 abstract description 7
• 238000007877 drug screening Methods 0.000 abstract description 4
• 235000001014 amino acid Nutrition 0.000 description 142
• 229940024606 amino acid Drugs 0.000 description 137
• 235000018102 proteins Nutrition 0.000 description 91
• 230000014509 gene expression Effects 0.000 description 90
• 238000009739 binding Methods 0.000 description 55
• 241001465754 Metazoa Species 0.000 description 45
• 206010028980 Neoplasm Diseases 0.000 description 37
• 230000006870 function Effects 0.000 description 37
• 108020004414 DNA Proteins 0.000 description 34
• 238000003556 assay Methods 0.000 description 33
• 230000003834 intracellular effect Effects 0.000 description 31
• 108091006027 G proteins Proteins 0.000 description 30
• 102000030782 GTP binding Human genes 0.000 description 30
• 108091000058 GTP-Binding Proteins 0.000 description 30
• 239000000523 sample Substances 0.000 description 30
• 201000010099 disease Diseases 0.000 description 28
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 28
• 230000035772 mutation Effects 0.000 description 27
• 239000013604 expression vector Substances 0.000 description 24
• 230000009261 transgenic effect Effects 0.000 description 24
• 230000019491 signal transduction Effects 0.000 description 23
• 230000001105 regulatory effect Effects 0.000 description 19
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 18
• 230000004927 fusion Effects 0.000 description 18
• 230000004913 activation Effects 0.000 description 17
• 239000000203 mixture Substances 0.000 description 17
• 230000026731 phosphorylation Effects 0.000 description 17
• 238000006366 phosphorylation reaction Methods 0.000 description 17
• 108020001507 fusion proteins Proteins 0.000 description 16
• 102000037865 fusion proteins Human genes 0.000 description 16
• 125000000539 amino acid group Chemical group 0.000 description 15
• 230000000875 corresponding effect Effects 0.000 description 15
• 239000003814 drug Substances 0.000 description 15
• 239000000126 substance Substances 0.000 description 15
• 238000006467 substitution reaction Methods 0.000 description 15
• 108091026890 Coding region Proteins 0.000 description 14
• 108700019146 Transgenes Proteins 0.000 description 14
• 230000001154 acute effect Effects 0.000 description 14
• 210000000349 chromosome Anatomy 0.000 description 14
• 229940079593 drug Drugs 0.000 description 14
• 238000009396 hybridization Methods 0.000 description 14
• 230000004048 modification Effects 0.000 description 14
• 238000012986 modification Methods 0.000 description 14
• 238000002360 preparation method Methods 0.000 description 14
• 230000001225 therapeutic effect Effects 0.000 description 14
• 238000013518 transcription Methods 0.000 description 14
• 230000035897 transcription Effects 0.000 description 14
• 230000001684 chronic effect Effects 0.000 description 13
• 102000004190 Enzymes Human genes 0.000 description 12
• 108090000790 Enzymes Proteins 0.000 description 12
• 210000003719 b-lymphocyte Anatomy 0.000 description 12
• 229940088598 enzyme Drugs 0.000 description 12
• 230000013595 glycosylation Effects 0.000 description 12
• 210000004185 liver Anatomy 0.000 description 12
• 239000000463 material Substances 0.000 description 12
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 11
• IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 11
• 238000004458 analytical method Methods 0.000 description 11
• 229940095074 cyclic amp Drugs 0.000 description 11
• 238000006206 glycosylation reaction Methods 0.000 description 11
• 208000015181 infectious disease Diseases 0.000 description 11
• 230000007306 turnover Effects 0.000 description 11
• 201000009030 Carcinoma Diseases 0.000 description 10
• 230000001594 aberrant effect Effects 0.000 description 10
• 239000002253 acid Substances 0.000 description 10
• 230000001413 cellular effect Effects 0.000 description 10
• -1 e.g. Proteins 0.000 description 10
• 206010010356 Congenital anomaly Diseases 0.000 description 9
• MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 9
• 230000000692 anti-sense effect Effects 0.000 description 9
• 239000012472 biological sample Substances 0.000 description 9
• 230000015572 biosynthetic process Effects 0.000 description 9
• 210000001185 bone marrow Anatomy 0.000 description 9
• 239000003550 marker Substances 0.000 description 9
• 210000000130 stem cell Anatomy 0.000 description 9
• 238000012360 testing method Methods 0.000 description 9
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 8
• 239000012707 chemical precursor Substances 0.000 description 8
• 230000007423 decrease Effects 0.000 description 8
• 238000011161 development Methods 0.000 description 8
• 230000018109 developmental process Effects 0.000 description 8
• 238000000338 in vitro Methods 0.000 description 8
• 210000003734 kidney Anatomy 0.000 description 8
• 230000002093 peripheral effect Effects 0.000 description 8
• 239000002243 precursor Substances 0.000 description 8
• 239000000047 product Substances 0.000 description 8
• 230000004044 response Effects 0.000 description 8
• CNWINRVXAYPOMW-FCNJXWMTSA-N 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-1D-myo-inositol 4,5-biphosphate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O CNWINRVXAYPOMW-FCNJXWMTSA-N 0.000 description 7
• 239000004475 Arginine Substances 0.000 description 7
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 7
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
• 230000000890 antigenic effect Effects 0.000 description 7
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 7
• 210000001072 colon Anatomy 0.000 description 7
• 230000002068 genetic effect Effects 0.000 description 7
• 238000011065 in-situ storage Methods 0.000 description 7
• 230000001965 increasing effect Effects 0.000 description 7
• 238000003780 insertion Methods 0.000 description 7
• 230000037431 insertion Effects 0.000 description 7
• 230000003993 interaction Effects 0.000 description 7
• 210000004072 lung Anatomy 0.000 description 7
• 210000004698 lymphocyte Anatomy 0.000 description 7
• 210000003593 megakaryocyte Anatomy 0.000 description 7
• 210000004379 membrane Anatomy 0.000 description 7
• 239000012528 membrane Substances 0.000 description 7
• 230000004060 metabolic process Effects 0.000 description 7
• 210000000496 pancreas Anatomy 0.000 description 7
• 230000007170 pathology Effects 0.000 description 7
• 150000003905 phosphatidylinositols Chemical class 0.000 description 7
• 238000000746 purification Methods 0.000 description 7
• 210000000813 small intestine Anatomy 0.000 description 7
• 208000011580 syndromic disease Diseases 0.000 description 7
• 210000001541 thymus gland Anatomy 0.000 description 7
• 230000014616 translation Effects 0.000 description 7
• 238000013519 translation Methods 0.000 description 7
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
• 102000052052 Casein Kinase II Human genes 0.000 description 6
• 108010010919 Casein Kinase II Proteins 0.000 description 6
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 241000700605 Viruses Species 0.000 description 6
• 230000003321 amplification Effects 0.000 description 6
• 210000004556 brain Anatomy 0.000 description 6
• 201000011510 cancer Diseases 0.000 description 6
• 238000003776 cleavage reaction Methods 0.000 description 6
• 230000006378 damage Effects 0.000 description 6
• 238000012217 deletion Methods 0.000 description 6
• 230000037430 deletion Effects 0.000 description 6
• SLPJGDQJLTYWCI-UHFFFAOYSA-N dimethyl-(4,5,6,7-tetrabromo-1h-benzoimidazol-2-yl)-amine Chemical compound BrC1=C(Br)C(Br)=C2NC(N(C)C)=NC2=C1Br SLPJGDQJLTYWCI-UHFFFAOYSA-N 0.000 description 6
• 206010014599 encephalitis Diseases 0.000 description 6
• 238000005755 formation reaction Methods 0.000 description 6
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
• 210000002216 heart Anatomy 0.000 description 6
• 238000007901 in situ hybridization Methods 0.000 description 6
• 238000001727 in vivo Methods 0.000 description 6
• 208000014674 injury Diseases 0.000 description 6
• 208000032839 leukemia Diseases 0.000 description 6
• 201000005962 mycosis fungoides Diseases 0.000 description 6
• 238000003199 nucleic acid amplification method Methods 0.000 description 6
• 210000000287 oocyte Anatomy 0.000 description 6
• 239000008194 pharmaceutical composition Substances 0.000 description 6
• 238000012545 processing Methods 0.000 description 6
• 210000002307 prostate Anatomy 0.000 description 6
• 230000007017 scission Effects 0.000 description 6
• 238000012163 sequencing technique Methods 0.000 description 6
• 210000002027 skeletal muscle Anatomy 0.000 description 6
• 239000000243 solution Substances 0.000 description 6
• 210000000952 spleen Anatomy 0.000 description 6
• 238000003786 synthesis reaction Methods 0.000 description 6
• 210000001550 testis Anatomy 0.000 description 6
• 210000004291 uterus Anatomy 0.000 description 6
• 208000019553 vascular disease Diseases 0.000 description 6
• 108090000994 Catalytic RNA Proteins 0.000 description 5
• 102000053642 Catalytic RNA Human genes 0.000 description 5
• 206010018364 Glomerulonephritis Diseases 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• 241000238631 Hexapoda Species 0.000 description 5
• 108020004511 Recombinant DNA Proteins 0.000 description 5
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
• 108010091086 Recombinases Proteins 0.000 description 5
• 102000018120 Recombinases Human genes 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 208000027418 Wounds and injury Diseases 0.000 description 5
• 208000007502 anemia Diseases 0.000 description 5
• 230000001580 bacterial effect Effects 0.000 description 5
• 210000000170 cell membrane Anatomy 0.000 description 5
• 230000008859 change Effects 0.000 description 5
• 230000002759 chromosomal effect Effects 0.000 description 5
• 230000007812 deficiency Effects 0.000 description 5
• 239000003623 enhancer Substances 0.000 description 5
• 210000003527 eukaryotic cell Anatomy 0.000 description 5
• 238000001415 gene therapy Methods 0.000 description 5
• 208000017169 kidney disease Diseases 0.000 description 5
• 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 5
• 230000002974 pharmacogenomic effect Effects 0.000 description 5
• 210000002826 placenta Anatomy 0.000 description 5
• 108091092562 ribozyme Proteins 0.000 description 5
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 5
• 208000030507 AIDS Diseases 0.000 description 4
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
• 208000003200 Adenoma Diseases 0.000 description 4
• 108020005544 Antisense RNA Proteins 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
• 241000894006 Bacteria Species 0.000 description 4
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 4
• 241000588724 Escherichia coli Species 0.000 description 4
• 206010019280 Heart failures Diseases 0.000 description 4
• 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 4
• 206010020772 Hypertension Diseases 0.000 description 4
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 4
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
• 102000003923 Protein Kinase C Human genes 0.000 description 4
• 108090000315 Protein Kinase C Proteins 0.000 description 4
• 108090000820 Rhodopsin Proteins 0.000 description 4
• 206010039491 Sarcoma Diseases 0.000 description 4
• 230000002159 abnormal effect Effects 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 102000030621 adenylate cyclase Human genes 0.000 description 4
• 108060000200 adenylate cyclase Proteins 0.000 description 4
• 230000004075 alteration Effects 0.000 description 4
• 239000000427 antigen Substances 0.000 description 4
• 108091007433 antigens Proteins 0.000 description 4
• 102000036639 antigens Human genes 0.000 description 4
• 210000004970 cd4 cell Anatomy 0.000 description 4
• 238000000423 cell based assay Methods 0.000 description 4
• 230000007882 cirrhosis Effects 0.000 description 4
• 208000019425 cirrhosis of liver Diseases 0.000 description 4
• 238000010367 cloning Methods 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 238000009826 distribution Methods 0.000 description 4
• 238000007878 drug screening assay Methods 0.000 description 4
• 210000001671 embryonic stem cell Anatomy 0.000 description 4
• 238000005516 engineering process Methods 0.000 description 4
• 208000010227 enterocolitis Diseases 0.000 description 4
• 239000012530 fluid Substances 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 238000002744 homologous recombination Methods 0.000 description 4
• 230000006801 homologous recombination Effects 0.000 description 4
• 206010020718 hyperplasia Diseases 0.000 description 4
• 230000002163 immunogen Effects 0.000 description 4
• 230000001939 inductive effect Effects 0.000 description 4
• 230000002757 inflammatory effect Effects 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 210000001165 lymph node Anatomy 0.000 description 4
• 208000003747 lymphoid leukemia Diseases 0.000 description 4
• 210000004962 mammalian cell Anatomy 0.000 description 4
• 210000001161 mammalian embryo Anatomy 0.000 description 4
• 239000011159 matrix material Substances 0.000 description 4
• 201000011475 meningoencephalitis Diseases 0.000 description 4
• 238000012544 monitoring process Methods 0.000 description 4
• 230000007498 myristoylation Effects 0.000 description 4
• 210000000822 natural killer cell Anatomy 0.000 description 4
• 208000015122 neurodegenerative disease Diseases 0.000 description 4
• 230000037361 pathway Effects 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 230000005855 radiation Effects 0.000 description 4
• 108091008146 restriction endonucleases Proteins 0.000 description 4
• 230000028327 secretion Effects 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 230000002992 thymic effect Effects 0.000 description 4
• 208000008732 thymoma Diseases 0.000 description 4
• 238000011277 treatment modality Methods 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 3
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
• 206010003571 Astrocytoma Diseases 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 208000004434 Calcinosis Diseases 0.000 description 3
• 108091006146 Channels Proteins 0.000 description 3
• 208000026372 Congenital cystic kidney disease Diseases 0.000 description 3
• 241000701022 Cytomegalovirus Species 0.000 description 3
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
• 108091060211 Expressed sequence tag Proteins 0.000 description 3
• 206010016654 Fibrosis Diseases 0.000 description 3
• 206010071602 Genetic polymorphism Diseases 0.000 description 3
• 108010024636 Glutathione Proteins 0.000 description 3
• UXDDRFCJKNROTO-UHFFFAOYSA-N Glycerol 1,2-diacetate Chemical compound CC(=O)OCC(CO)OC(C)=O UXDDRFCJKNROTO-UHFFFAOYSA-N 0.000 description 3
• 206010019799 Hepatitis viral Diseases 0.000 description 3
• 208000017604 Hodgkin disease Diseases 0.000 description 3
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 3
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
• 208000010159 IgA glomerulonephritis Diseases 0.000 description 3
• 206010061216 Infarction Diseases 0.000 description 3
• CIPFCGZLFXVXBG-FTSGZOCFSA-N Inositol 1,3,4,5-tetraphosphate Chemical compound O[C@H]1C(OP(O)(O)=O)[C@H](O)[C@@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H]1OP(O)(O)=O CIPFCGZLFXVXBG-FTSGZOCFSA-N 0.000 description 3
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
• 108060001084 Luciferase Proteins 0.000 description 3
• 239000005089 Luciferase Substances 0.000 description 3
• 206010025323 Lymphomas Diseases 0.000 description 3
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
• 201000009906 Meningitis Diseases 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 208000034578 Multiple myelomas Diseases 0.000 description 3
• 208000001089 Multiple system atrophy Diseases 0.000 description 3
• 208000009905 Neurofibromatoses Diseases 0.000 description 3
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
• 208000018737 Parkinson disease Diseases 0.000 description 3
• 208000002163 Phyllodes Tumor Diseases 0.000 description 3
• 206010035226 Plasma cell myeloma Diseases 0.000 description 3
• 108010076504 Protein Sorting Signals Proteins 0.000 description 3
• 208000006265 Renal cell carcinoma Diseases 0.000 description 3
• 102100040756 Rhodopsin Human genes 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 206010041660 Splenomegaly Diseases 0.000 description 3
• 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 3
• 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 3
• 206010047115 Vasculitis Diseases 0.000 description 3
• 239000011324 bead Substances 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 229960002685 biotin Drugs 0.000 description 3
• 235000020958 biotin Nutrition 0.000 description 3
• 239000011616 biotin Substances 0.000 description 3
• 210000000481 breast Anatomy 0.000 description 3
• 230000002308 calcification Effects 0.000 description 3
• 208000002458 carcinoid tumor Diseases 0.000 description 3
• 210000004671 cell-free system Anatomy 0.000 description 3
• 108700010039 chimeric receptor Proteins 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• 239000003184 complementary RNA Substances 0.000 description 3
• 208000031513 cyst Diseases 0.000 description 3
• 210000000805 cytoplasm Anatomy 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 230000004069 differentiation Effects 0.000 description 3
• 239000002612 dispersion medium Substances 0.000 description 3
• 230000000857 drug effect Effects 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 238000001476 gene delivery Methods 0.000 description 3
• 229960003180 glutathione Drugs 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 208000007475 hemolytic anemia Diseases 0.000 description 3
• 230000002209 hydrophobic effect Effects 0.000 description 3
• 208000015210 hypertensive heart disease Diseases 0.000 description 3
• 230000001771 impaired effect Effects 0.000 description 3
• 230000007574 infarction Effects 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 201000006334 interstitial nephritis Diseases 0.000 description 3
• 230000003902 lesion Effects 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 208000019423 liver disease Diseases 0.000 description 3
• 238000012423 maintenance Methods 0.000 description 3
• 230000003211 malignant effect Effects 0.000 description 3
• 238000013507 mapping Methods 0.000 description 3
• 208000004396 mastitis Diseases 0.000 description 3
• 201000008350 membranous glomerulonephritis Diseases 0.000 description 3
• 206010061289 metastatic neoplasm Diseases 0.000 description 3
• 244000005700 microbiome Species 0.000 description 3
• 238000010369 molecular cloning Methods 0.000 description 3
• 201000004931 neurofibromatosis Diseases 0.000 description 3
• 208000008494 pericarditis Diseases 0.000 description 3
• 239000013612 plasmid Substances 0.000 description 3
• 230000008488 polyadenylation Effects 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 230000002062 proliferating effect Effects 0.000 description 3
• 230000004952 protein activity Effects 0.000 description 3
• 238000010188 recombinant method Methods 0.000 description 3
• 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
• 241000894007 species Species 0.000 description 3
• 238000010561 standard procedure Methods 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 206010043778 thyroiditis Diseases 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• 238000002054 transplantation Methods 0.000 description 3
• 201000008827 tuberculosis Diseases 0.000 description 3
• 241000701447 unidentified baculovirus Species 0.000 description 3
• 241001515965 unidentified phage Species 0.000 description 3
• 241001430294 unidentified retrovirus Species 0.000 description 3
• 230000002792 vascular Effects 0.000 description 3
• 239000003981 vehicle Substances 0.000 description 3
• 201000001862 viral hepatitis Diseases 0.000 description 3
• 239000013603 viral vector Substances 0.000 description 3
• 230000003612 virological effect Effects 0.000 description 3
• 230000005730 ADP ribosylation Effects 0.000 description 2
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
• 206010001233 Adenoma benign Diseases 0.000 description 2
• 208000024985 Alport syndrome Diseases 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• 206010002329 Aneurysm Diseases 0.000 description 2
• 208000032467 Aplastic anaemia Diseases 0.000 description 2
• 206010003694 Atrophy Diseases 0.000 description 2
• 208000012526 B-cell neoplasm Diseases 0.000 description 2
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
• 102100026189 Beta-galactosidase Human genes 0.000 description 2
• BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
• 201000006474 Brain Ischemia Diseases 0.000 description 2
• 208000007257 Budd-Chiari syndrome Diseases 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 206010008120 Cerebral ischaemia Diseases 0.000 description 2
• 206010009657 Clostridium difficile colitis Diseases 0.000 description 2
• 108091033380 Coding strand Proteins 0.000 description 2
• 102000008186 Collagen Human genes 0.000 description 2
• 108010035532 Collagen Proteins 0.000 description 2
• 206010011703 Cyanosis Diseases 0.000 description 2
• 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 2
• 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
• 102000053602 DNA Human genes 0.000 description 2
• 208000012239 Developmental disease Diseases 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 108010074860 Factor Xa Proteins 0.000 description 2
• 208000007659 Fibroadenoma Diseases 0.000 description 2
• 206010053717 Fibrous histiocytoma Diseases 0.000 description 2
• 201000011240 Frontotemporal dementia Diseases 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 206010018366 Glomerulonephritis acute Diseases 0.000 description 2
• 206010018374 Glomerulonephritis minimal lesion Diseases 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 208000032843 Hemorrhage Diseases 0.000 description 2
• 208000007514 Herpes zoster Diseases 0.000 description 2
• SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 206010021263 IgA nephropathy Diseases 0.000 description 2
• 108060003951 Immunoglobulin Proteins 0.000 description 2
• 206010062016 Immunosuppression Diseases 0.000 description 2
• 208000020340 Immunotactoid glomerulopathy Diseases 0.000 description 2
• 208000001019 Inborn Errors Metabolism Diseases 0.000 description 2
• 208000009164 Islet Cell Adenoma Diseases 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• 208000004883 Lipoid Nephrosis Diseases 0.000 description 2
• 208000019693 Lung disease Diseases 0.000 description 2
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
• 208000007054 Medullary Carcinoma Diseases 0.000 description 2
• 210000002361 Megakaryocyte Progenitor Cell Anatomy 0.000 description 2
• 208000003351 Melanosis Diseases 0.000 description 2
• 206010028851 Necrosis Diseases 0.000 description 2
• 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
• 101710163270 Nuclease Proteins 0.000 description 2
• 206010030113 Oedema Diseases 0.000 description 2
• 108700026244 Open Reading Frames Proteins 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 206010033645 Pancreatitis Diseases 0.000 description 2
• 208000005228 Pericardial Effusion Diseases 0.000 description 2
• 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 108010001441 Phosphopeptides Proteins 0.000 description 2
• 108091000080 Phosphotransferase Proteins 0.000 description 2
• 208000000609 Pick Disease of the Brain Diseases 0.000 description 2
• 208000024571 Pick disease Diseases 0.000 description 2
• 208000002151 Pleural effusion Diseases 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 201000009454 Portal vein thrombosis Diseases 0.000 description 2
• 102000004257 Potassium Channel Human genes 0.000 description 2
• 208000032236 Predisposition to disease Diseases 0.000 description 2
• 208000024777 Prion disease Diseases 0.000 description 2
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
• 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 2
• 206010037394 Pulmonary haemorrhage Diseases 0.000 description 2
• 206010037423 Pulmonary oedema Diseases 0.000 description 2
• 101710146873 Receptor-binding protein Proteins 0.000 description 2
• 108700008625 Reporter Genes Proteins 0.000 description 2
• 201000010208 Seminoma Diseases 0.000 description 2
• 208000009359 Sezary Syndrome Diseases 0.000 description 2
• 208000021388 Sezary disease Diseases 0.000 description 2
• 206010058339 Splenitis Diseases 0.000 description 2
• 108010090804 Streptavidin Proteins 0.000 description 2
• 201000009594 Systemic Scleroderma Diseases 0.000 description 2
• 206010042953 Systemic sclerosis Diseases 0.000 description 2
• 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 2
• 208000025317 T-cell and NK-cell neoplasm Diseases 0.000 description 2
• 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 2
• 201000009365 Thymic carcinoma Diseases 0.000 description 2
• 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 2
• 102000014384 Type C Phospholipases Human genes 0.000 description 2
• 108010079194 Type C Phospholipases Proteins 0.000 description 2
• 108091023045 Untranslated Region Proteins 0.000 description 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
• 206010047112 Vasculitides Diseases 0.000 description 2
• 229930003270 Vitamin B Natural products 0.000 description 2
• 210000002593 Y chromosome Anatomy 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 231100000851 acute glomerulonephritis Toxicity 0.000 description 2
• 238000007792 addition Methods 0.000 description 2
• 208000009956 adenocarcinoma Diseases 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• 206010002022 amyloidosis Diseases 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 229940121375 antifungal agent Drugs 0.000 description 2
• 206010003230 arteritis Diseases 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 229940009098 aspartate Drugs 0.000 description 2
• 230000037444 atrophy Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 108010005774 beta-Galactosidase Proteins 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 238000004166 bioassay Methods 0.000 description 2
• 210000002459 blastocyst Anatomy 0.000 description 2
• 230000017531 blood circulation Effects 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 238000010322 bone marrow transplantation Methods 0.000 description 2
• 201000003149 breast fibroadenoma Diseases 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 230000000747 cardiac effect Effects 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 239000013592 cell lysate Substances 0.000 description 2
• 206010008118 cerebral infarction Diseases 0.000 description 2
• 208000026106 cerebrovascular disease Diseases 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 229920001436 collagen Polymers 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 230000001276 controlling effect Effects 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• 230000001054 cortical effect Effects 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 230000007850 degeneration Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 238000002405 diagnostic procedure Methods 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 239000012636 effector Substances 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 206010014665 endocarditis Diseases 0.000 description 2
• 230000002357 endometrial effect Effects 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 238000001976 enzyme digestion Methods 0.000 description 2
• 201000010063 epididymitis Diseases 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 230000003619 fibrillary effect Effects 0.000 description 2
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
• 230000006251 gamma-carboxylation Effects 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 210000004602 germ cell Anatomy 0.000 description 2
• 208000005017 glioblastoma Diseases 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 210000002360 granulocyte-macrophage progenitor cell Anatomy 0.000 description 2
• 208000019622 heart disease Diseases 0.000 description 2
• 230000002008 hemorrhagic effect Effects 0.000 description 2
• 230000002440 hepatic effect Effects 0.000 description 2
• 208000006454 hepatitis Diseases 0.000 description 2
• 231100000283 hepatitis Toxicity 0.000 description 2
• 208000003215 hereditary nephritis Diseases 0.000 description 2
• 230000033444 hydroxylation Effects 0.000 description 2
• 238000005805 hydroxylation reaction Methods 0.000 description 2
• 230000009610 hypersensitivity Effects 0.000 description 2
• 230000001631 hypertensive effect Effects 0.000 description 2
• 102000018358 immunoglobulin Human genes 0.000 description 2
• 238000001114 immunoprecipitation Methods 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 208000016245 inborn errors of metabolism Diseases 0.000 description 2
• 230000002458 infectious effect Effects 0.000 description 2
• 201000007119 infective endocarditis Diseases 0.000 description 2
• 208000027866 inflammatory disease Diseases 0.000 description 2
• 208000015978 inherited metabolic disease Diseases 0.000 description 2
• 229960000367 inositol Drugs 0.000 description 2
• 201000003159 intraductal papilloma Diseases 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 239000007951 isotonicity adjuster Substances 0.000 description 2
• 201000003265 lymphadenitis Diseases 0.000 description 2
• 201000011649 lymphoblastic lymphoma Diseases 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
• 230000011987 methylation Effects 0.000 description 2
• 238000007069 methylation reaction Methods 0.000 description 2
• 238000000520 microinjection Methods 0.000 description 2
• 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 2
• 210000003470 mitochondria Anatomy 0.000 description 2
• 201000005895 multinodular goiter Diseases 0.000 description 2
• 208000031225 myocardial ischemia Diseases 0.000 description 2
• 230000017074 necrotic cell death Effects 0.000 description 2
• 230000002956 necrotizing effect Effects 0.000 description 2
• 230000001613 neoplastic effect Effects 0.000 description 2
• 201000008383 nephritis Diseases 0.000 description 2
• 201000002648 nephronophthisis Diseases 0.000 description 2
• 201000009925 nephrosclerosis Diseases 0.000 description 2
• 210000000653 nervous system Anatomy 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 2
• 201000010198 papillary carcinoma Diseases 0.000 description 2
• 208000012111 paraneoplastic syndrome Diseases 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 239000000825 pharmaceutical preparation Substances 0.000 description 2
• 235000021317 phosphate Nutrition 0.000 description 2
• 239000002953 phosphate buffered saline Substances 0.000 description 2
• 102000020233 phosphotransferase Human genes 0.000 description 2
• 201000006292 polyarteritis nodosa Diseases 0.000 description 2
• 208000030761 polycystic kidney disease Diseases 0.000 description 2
• 102000054765 polymorphisms of proteins Human genes 0.000 description 2
• 230000004481 post-translational protein modification Effects 0.000 description 2
• 108020001213 potassium channel Proteins 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 230000002797 proteolythic effect Effects 0.000 description 2
• 208000005333 pulmonary edema Diseases 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
• 230000003248 secreting effect Effects 0.000 description 2
• 208000007056 sickle cell anemia Diseases 0.000 description 2
• 210000003491 skin Anatomy 0.000 description 2
• 208000017520 skin disease Diseases 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 210000001082 somatic cell Anatomy 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 238000012916 structural analysis Methods 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 230000019635 sulfation Effects 0.000 description 2
• 238000005670 sulfation reaction Methods 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 208000006379 syphilis Diseases 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 210000001685 thyroid gland Anatomy 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 108700012359 toxins Proteins 0.000 description 2
• 238000010361 transduction Methods 0.000 description 2
• 230000026683 transduction Effects 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 238000010798 ubiquitination Methods 0.000 description 2
• 230000034512 ubiquitination Effects 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• 201000002327 urinary tract obstruction Diseases 0.000 description 2
• 235000019156 vitamin B Nutrition 0.000 description 2
• 239000011720 vitamin B Substances 0.000 description 2
• KUHSEZKIEJYEHN-BXRBKJIMSA-N (2s)-2-amino-3-hydroxypropanoic acid;(2s)-2-aminopropanoic acid Chemical compound C[C@H](N)C(O)=O.OC[C@H](N)C(O)=O KUHSEZKIEJYEHN-BXRBKJIMSA-N 0.000 description 1
• PSLCKQYQNVNTQI-BHFSHLQUSA-N (2s)-2-aminobutanedioic acid;(2s)-2-aminopentanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCC(O)=O PSLCKQYQNVNTQI-BHFSHLQUSA-N 0.000 description 1
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 1
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
• CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
• 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 1
• 102000012440 Acetylcholinesterase Human genes 0.000 description 1
• 108010022752 Acetylcholinesterase Proteins 0.000 description 1
• 208000002874 Acne Vulgaris Diseases 0.000 description 1
• 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 1
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• 208000005641 Adenomyosis Diseases 0.000 description 1
• 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
• 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
• 108010000239 Aequorin Proteins 0.000 description 1
• 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 206010001881 Alveolar proteinosis Diseases 0.000 description 1
• 208000030760 Anaemia of chronic disease Diseases 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
• 208000009945 Angiomatoid fibrous histiocytoma Diseases 0.000 description 1
• 206010051810 Angiomyolipoma Diseases 0.000 description 1
• 201000003076 Angiosarcoma Diseases 0.000 description 1
• 206010058079 Anomalous pulmonary venous connection Diseases 0.000 description 1
• 206010002659 Anovulatory cycle Diseases 0.000 description 1
• 108020004491 Antisense DNA Proteins 0.000 description 1
• 208000006179 Aortic Coarctation Diseases 0.000 description 1
• 206010002961 Aplasia Diseases 0.000 description 1
• 206010003226 Arteriovenous fistula Diseases 0.000 description 1
• 206010003399 Arthropod bite Diseases 0.000 description 1
• 206010060969 Arthropod infestation Diseases 0.000 description 1
• 206010003402 Arthropod sting Diseases 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 208000031504 Asymptomatic Infections Diseases 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 206010003598 Atelectasis Diseases 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 206010063836 Atrioventricular septal defect Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 208000000412 Avitaminosis Diseases 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 208000004597 Bacillary angiomatosis Diseases 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 208000025760 Benign familial haematuria Diseases 0.000 description 1
• 206010004552 Bicuspid aortic valve Diseases 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000015163 Biliary Tract disease Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000004020 Brain Abscess Diseases 0.000 description 1
• 206010048962 Brain oedema Diseases 0.000 description 1
• 206010006143 Brain stem glioma Diseases 0.000 description 1
• 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
• 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
• 206010006458 Bronchitis chronic Diseases 0.000 description 1
• 206010006500 Brucellosis Diseases 0.000 description 1
• 208000033386 Buerger disease Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• 201000004085 CLL/SLL Diseases 0.000 description 1
• 208000034598 Caecitis Diseases 0.000 description 1
• 102000055006 Calcitonin Human genes 0.000 description 1
• 108010001789 Calcitonin Receptors Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 102000003922 Calcium Channels Human genes 0.000 description 1
• 108090000312 Calcium Channels Proteins 0.000 description 1
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
• 206010007027 Calculus urinary Diseases 0.000 description 1
• 208000022526 Canavan disease Diseases 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
• 201000000274 Carcinosarcoma Diseases 0.000 description 1
• 208000021565 Cardiac Papillary Fibroelastoma Diseases 0.000 description 1
• 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
• 208000006029 Cardiomegaly Diseases 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 206010008570 Chloasma Diseases 0.000 description 1
• 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
• 206010008635 Cholestasis Diseases 0.000 description 1
• 206010049055 Cholestasis of pregnancy Diseases 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• 208000016216 Choristoma Diseases 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 206010009807 Coarctation of the aorta Diseases 0.000 description 1
• 108700010070 Codon Usage Proteins 0.000 description 1
• 208000015943 Coeliac disease Diseases 0.000 description 1
• 206010056979 Colitis microscopic Diseases 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 208000002330 Congenital Heart Defects Diseases 0.000 description 1
• 206010010539 Congenital megacolon Diseases 0.000 description 1
• 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
• 102000012437 Copper-Transporting ATPases Human genes 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 108010051219 Cre recombinase Proteins 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 206010011498 Cryptorchism Diseases 0.000 description 1
• 108700020473 Cyclic AMP Receptor Proteins 0.000 description 1
• 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
• 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 239000003298 DNA probe Substances 0.000 description 1
• 238000001712 DNA sequencing Methods 0.000 description 1
• XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 208000016192 Demyelinating disease Diseases 0.000 description 1
• 206010012305 Demyelination Diseases 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• 241000168726 Dictyostelium discoideum Species 0.000 description 1
• 206010060902 Diffuse alveolar damage Diseases 0.000 description 1
• 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
• 108010001394 Disaccharidases Proteins 0.000 description 1
• 208000002251 Dissecting Aneurysm Diseases 0.000 description 1
• 206010013654 Drug abuse Diseases 0.000 description 1
• 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
• 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 1
• 206010014096 Echinococciasis Diseases 0.000 description 1
• 208000009366 Echinococcosis Diseases 0.000 description 1
• 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 206010014561 Emphysema Diseases 0.000 description 1
• 206010014612 Encephalitis viral Diseases 0.000 description 1
• 206010014666 Endocarditis bacterial Diseases 0.000 description 1
• 206010062608 Endocarditis noninfective Diseases 0.000 description 1
• 208000027666 Endometrial Stromal Tumors Diseases 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 206010048554 Endothelial dysfunction Diseases 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 description 1
• 108010013369 Enteropeptidase Proteins 0.000 description 1
• 102100029727 Enteropeptidase Human genes 0.000 description 1
• 206010014950 Eosinophilia Diseases 0.000 description 1
• 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
• 208000000979 Erythema Induratum Diseases 0.000 description 1
• 206010015218 Erythema multiforme Diseases 0.000 description 1
• 206010015226 Erythema nodosum Diseases 0.000 description 1
• 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
• 206010049466 Erythroblastosis Diseases 0.000 description 1
• 208000036566 Erythroleukaemia Diseases 0.000 description 1
• 241000702191 Escherichia virus P1 Species 0.000 description 1
• 108091029865 Exogenous DNA Proteins 0.000 description 1
• 206010061846 Extradural abscess Diseases 0.000 description 1
• 108010046276 FLP recombinase Proteins 0.000 description 1
• 208000023281 Fallot tetralogy Diseases 0.000 description 1
• 206010061857 Fat necrosis Diseases 0.000 description 1
• 206010068279 Fibrillary glomerulonephritis Diseases 0.000 description 1
• 206010052072 Fibrosing colonopathy Diseases 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• 206010017065 Foster-Kennedy Syndrome Diseases 0.000 description 1
• 208000024412 Friedreich ataxia Diseases 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 208000025499 G6PD deficiency Diseases 0.000 description 1
• 102000027582 GPCRs class B Human genes 0.000 description 1
• 108091008883 GPCRs class B Proteins 0.000 description 1
• 108091008881 GPCRs class D Proteins 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 206010017918 Gastroenteritis viral Diseases 0.000 description 1
• 208000015872 Gaucher disease Diseases 0.000 description 1
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
• 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
• 206010018341 Gliosis Diseases 0.000 description 1
• 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
• 208000022461 Glomerular disease Diseases 0.000 description 1
• 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
• 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
• 201000005618 Glomus Tumor Diseases 0.000 description 1
• 206010018381 Glomus tumour Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 206010018444 Glucose-6-phosphate dehydrogenase deficiency Diseases 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 102000005720 Glutathione transferase Human genes 0.000 description 1
• 108010070675 Glutathione transferase Proteins 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 108010001483 Glycogen Synthase Proteins 0.000 description 1
• 206010018498 Goitre Diseases 0.000 description 1
• 206010018612 Gonorrhoea Diseases 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 208000002628 Granulomatous mastitis Diseases 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 206010018852 Haematoma Diseases 0.000 description 1
• 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
• 208000002927 Hamartoma Diseases 0.000 description 1
• 208000001204 Hashimoto Disease Diseases 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 208000006050 Hemangiopericytoma Diseases 0.000 description 1
• 208000001258 Hemangiosarcoma Diseases 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 208000018565 Hemochromatosis Diseases 0.000 description 1
• 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
• 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
• 206010019663 Hepatic failure Diseases 0.000 description 1
• 206010019695 Hepatic neoplasm Diseases 0.000 description 1
• 206010019713 Hepatic vein thrombosis Diseases 0.000 description 1
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
• 208000004592 Hirschsprung disease Diseases 0.000 description 1
• 201000002563 Histoplasmosis Diseases 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
• 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
• 241000725303 Human immunodeficiency virus Species 0.000 description 1
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 206010020523 Hydromyelia Diseases 0.000 description 1
• 241000271915 Hydrophis Species 0.000 description 1
• 208000037147 Hypercalcaemia Diseases 0.000 description 1
• 206010020850 Hyperthyroidism Diseases 0.000 description 1
• 208000013016 Hypoglycemia Diseases 0.000 description 1
• 206010058558 Hypoperfusion Diseases 0.000 description 1
• 208000001953 Hypotension Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• 108091008585 IP3 receptors Proteins 0.000 description 1
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
• 208000009995 Idiopathic pulmonary hemosiderosis Diseases 0.000 description 1
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
• 208000031814 IgA Vasculitis Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 208000007746 Immunologic Deficiency Syndromes Diseases 0.000 description 1
• 206010067871 Immunotactoid glomerulonephritis Diseases 0.000 description 1
• 206010021531 Impetigo Diseases 0.000 description 1
• 206010070911 Inferior vena cava syndrome Diseases 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 108020005350 Initiator Codon Proteins 0.000 description 1
• 102000007640 Inositol 1,4,5-Trisphosphate Receptors Human genes 0.000 description 1
• 208000035478 Interatrial communication Diseases 0.000 description 1
• 208000029523 Interstitial Lung disease Diseases 0.000 description 1
• 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
• 201000008450 Intracranial aneurysm Diseases 0.000 description 1
• 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
• 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
• 206010023126 Jaundice Diseases 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 208000011200 Kawasaki disease Diseases 0.000 description 1
• 208000002260 Keloid Diseases 0.000 description 1
• 206010023330 Keloid scar Diseases 0.000 description 1
• 206010023347 Keratoacanthoma Diseases 0.000 description 1
• 208000028226 Krabbe disease Diseases 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 108010059881 Lactase Proteins 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 208000004552 Lacunar Stroke Diseases 0.000 description 1
• 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
• 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• 208000006136 Leigh Disease Diseases 0.000 description 1
• 208000017507 Leigh syndrome Diseases 0.000 description 1
• 208000018142 Leiomyosarcoma Diseases 0.000 description 1
• 208000004554 Leishmaniasis Diseases 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 201000004462 Leydig Cell Tumor Diseases 0.000 description 1
• 208000024369 Libman-Sacks endocarditis Diseases 0.000 description 1
• 206010024612 Lipoma Diseases 0.000 description 1
• 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 206010025102 Lung infiltration Diseases 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 206010025219 Lymphangioma Diseases 0.000 description 1
• 206010025282 Lymphoedema Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
• 208000035771 Malignant Sertoli-Leydig cell tumor of the ovary Diseases 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 206010026730 Mammary duct ectasia Diseases 0.000 description 1
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
• 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
• 208000010728 Meckel diverticulum Diseases 0.000 description 1
• 208000003382 Mediastinal Cyst Diseases 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
• 206010027145 Melanocytic naevus Diseases 0.000 description 1
• 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 235000004357 Mentha x piperita Nutrition 0.000 description 1
• 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
• 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 1
• 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 1
• 206010054949 Metaplasia Diseases 0.000 description 1
• 208000003430 Mitral Valve Prolapse Diseases 0.000 description 1
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
• 208000026072 Motor neurone disease Diseases 0.000 description 1
• 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
• 208000005647 Mumps Diseases 0.000 description 1
• 101100378134 Mus musculus Chrne gene Proteins 0.000 description 1
• 101100018717 Mus musculus Il1rl1 gene Proteins 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 208000021642 Muscular disease Diseases 0.000 description 1
• 108010021466 Mutant Proteins Proteins 0.000 description 1
• 102000008300 Mutant Proteins Human genes 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
• 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 description 1
• 206010028570 Myelopathy Diseases 0.000 description 1
• 208000014767 Myeloproliferative disease Diseases 0.000 description 1
• 208000021908 Myocardial disease Diseases 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• 201000009623 Myopathy Diseases 0.000 description 1
• 201000002481 Myositis Diseases 0.000 description 1
• 206010028665 Myxoedema Diseases 0.000 description 1
• PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
• 108010057466 NF-kappa B Proteins 0.000 description 1
• 102000003945 NF-kappa B Human genes 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 206010051606 Necrotising colitis Diseases 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 201000005118 Nephrogenic diabetes insipidus Diseases 0.000 description 1
• 206010029164 Nephrotic syndrome Diseases 0.000 description 1
• 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
• 201000004404 Neurofibroma Diseases 0.000 description 1
• 208000003019 Neurofibromatosis 1 Diseases 0.000 description 1
• 208000007256 Nevus Diseases 0.000 description 1
• 108091092724 Noncoding DNA Proteins 0.000 description 1
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
• 206010029888 Obliterative bronchiolitis Diseases 0.000 description 1
• 206010061876 Obstruction Diseases 0.000 description 1
• 208000036576 Obstructive uropathy Diseases 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 206010048757 Oncocytoma Diseases 0.000 description 1
• 241000233855 Orchidaceae Species 0.000 description 1
• 206010067472 Organising pneumonia Diseases 0.000 description 1
• 208000010191 Osteitis Deformans Diseases 0.000 description 1
• 102000016979 Other receptors Human genes 0.000 description 1
• 208000002063 Oxyphilic Adenoma Diseases 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 208000027868 Paget disease Diseases 0.000 description 1
• 206010033647 Pancreatitis acute Diseases 0.000 description 1
• 102000003982 Parathyroid hormone Human genes 0.000 description 1
• 108090000445 Parathyroid hormone Proteins 0.000 description 1
• 208000027089 Parkinsonian disease Diseases 0.000 description 1
• 206010034010 Parkinsonism Diseases 0.000 description 1
• 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
• 208000031481 Pathologic Constriction Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 201000004602 Peliosis Hepatis Diseases 0.000 description 1
• 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 1
• 206010034277 Pemphigoid Diseases 0.000 description 1
• 241000721454 Pemphigus Species 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 208000025584 Pericardial disease Diseases 0.000 description 1
• 206010034476 Pericardial haemorrhage Diseases 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 206010048734 Phakomatosis Diseases 0.000 description 1
• 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 206010071776 Phyllodes tumour Diseases 0.000 description 1
• 208000012641 Pigmentation disease Diseases 0.000 description 1
• 201000007286 Pilocytic astrocytoma Diseases 0.000 description 1
• 206010035610 Pleural Neoplasms Diseases 0.000 description 1
• 208000002664 Pleural Solitary Fibrous Tumor Diseases 0.000 description 1
• 208000000474 Poliomyelitis Diseases 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 241000097929 Porphyria Species 0.000 description 1
• 208000010642 Porphyrias Diseases 0.000 description 1
• 206010058989 Portal vein occlusion Diseases 0.000 description 1
• 206010036303 Post streptococcal glomerulonephritis Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 1
• 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
• 206010056658 Pseudocyst Diseases 0.000 description 1
• 206010037128 Pseudomembranous colitis Diseases 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
• 208000008640 Pulmonary Atresia Diseases 0.000 description 1
• 208000010378 Pulmonary Embolism Diseases 0.000 description 1
• 206010037368 Pulmonary congestion Diseases 0.000 description 1
• 208000006193 Pulmonary infarction Diseases 0.000 description 1
• 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
• 206010037597 Pyelonephritis acute Diseases 0.000 description 1
• 206010037601 Pyelonephritis chronic Diseases 0.000 description 1
• 206010037742 Rabies Diseases 0.000 description 1
• 208000034541 Rare lymphatic malformation Diseases 0.000 description 1
• 208000003782 Raynaud disease Diseases 0.000 description 1
• 208000012322 Raynaud phenomenon Diseases 0.000 description 1
• 206010065427 Reflux nephropathy Diseases 0.000 description 1
• 208000009527 Refractory anemia Diseases 0.000 description 1
• 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 1
• 208000004531 Renal Artery Obstruction Diseases 0.000 description 1
• 206010038378 Renal artery stenosis Diseases 0.000 description 1
• 206010038470 Renal infarct Diseases 0.000 description 1
• 206010038540 Renal tubular necrosis Diseases 0.000 description 1
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
• 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 1
• 206010038910 Retinitis Diseases 0.000 description 1
• 206010038997 Retroviral infections Diseases 0.000 description 1
• 208000005678 Rhabdomyoma Diseases 0.000 description 1
• AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 101150006985 STE2 gene Proteins 0.000 description 1
• 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 108091081021 Sense strand Proteins 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• 208000003274 Sertoli cell tumor Diseases 0.000 description 1
• 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
• 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
• 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
• 206010041659 Splenic vein thrombosis Diseases 0.000 description 1
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 108091081024 Start codon Proteins 0.000 description 1
• 241000187747 Streptomyces Species 0.000 description 1
• 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
• 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
• 208000001122 Superior Vena Cava Syndrome Diseases 0.000 description 1
• 206010042928 Syringomyelia Diseases 0.000 description 1
• 230000010782 T cell mediated cytotoxicity Effects 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
• 206010042970 T-cell chronic lymphocytic leukaemia Diseases 0.000 description 1
• 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
• 208000001106 Takayasu Arteritis Diseases 0.000 description 1
• 108020005038 Terminator Codon Proteins 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 201000003005 Tetralogy of Fallot Diseases 0.000 description 1
• JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 108010022394 Threonine synthase Proteins 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 108090000166 Thrombin receptors Proteins 0.000 description 1
• 102000003790 Thrombin receptors Human genes 0.000 description 1
• 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
• 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
• 206010051222 Toxic oil syndrome Diseases 0.000 description 1
• 206010070863 Toxicity to various agents Diseases 0.000 description 1
• 201000005485 Toxoplasmosis Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108020004566 Transfer RNA Proteins 0.000 description 1
• 108091007498 Transmembrane domain 2 Proteins 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• 208000002148 Transposition of Great Vessels Diseases 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
• 208000004387 Typhlitis Diseases 0.000 description 1
• 208000037386 Typhoid Diseases 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 206010046337 Urate nephropathy Diseases 0.000 description 1
• 208000024780 Urticaria Diseases 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 206010046996 Varicose vein Diseases 0.000 description 1
• 208000009443 Vascular Malformations Diseases 0.000 description 1
• 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
• 108090000643 Vasopressin Receptors Proteins 0.000 description 1
• 208000012346 Venoocclusive disease Diseases 0.000 description 1
• 206010047249 Venous thrombosis Diseases 0.000 description 1
• 206010047505 Visceral leishmaniasis Diseases 0.000 description 1
• 206010047627 Vitamin deficiencies Diseases 0.000 description 1
• 206010066969 Vitello-intestinal duct remnant Diseases 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 102000003734 Voltage-Gated Potassium Channels Human genes 0.000 description 1
• 108090000013 Voltage-Gated Potassium Channels Proteins 0.000 description 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
• 208000027207 Whipple disease Diseases 0.000 description 1
• 208000018839 Wilson disease Diseases 0.000 description 1
• 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
• 206010048215 Xanthomatosis Diseases 0.000 description 1
• 208000012018 Yolk sac tumor Diseases 0.000 description 1
• MMWCIQZXVOZEGG-NCGNNJKGSA-N [(1r,2s,3s,4r,5r,6r)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-NCGNNJKGSA-N 0.000 description 1
• 208000002223 abdominal aortic aneurysm Diseases 0.000 description 1
• 208000004622 abetalipoproteinemia Diseases 0.000 description 1
• 206010000269 abscess Diseases 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 201000010272 acanthosis nigricans Diseases 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 229940022698 acetylcholinesterase Drugs 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 206010000496 acne Diseases 0.000 description 1
• 208000011039 acquired metabolic disease Diseases 0.000 description 1
• 208000009621 actinic keratosis Diseases 0.000 description 1
• 230000036982 action potential Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
• 208000021841 acute erythroid leukemia Diseases 0.000 description 1
• 208000005652 acute fatty liver of pregnancy Diseases 0.000 description 1
• 201000003229 acute pancreatitis Diseases 0.000 description 1
• 201000005638 acute proliferative glomerulonephritis Diseases 0.000 description 1
• 201000001555 acute pyelonephritis Diseases 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 201000006966 adult T-cell leukemia Diseases 0.000 description 1
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 238000012867 alanine scanning Methods 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• HESIBZMZTMHXQS-UHFFFAOYSA-M alumanyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[AlH2] HESIBZMZTMHXQS-UHFFFAOYSA-M 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 150000001408 amides Chemical group 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
• 208000022400 anemia due to chronic disease Diseases 0.000 description 1
• 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 150000001450 anions Chemical group 0.000 description 1
• 230000000843 anti-fungal effect Effects 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000003816 antisense DNA Substances 0.000 description 1
• 206010002895 aortic dissection Diseases 0.000 description 1
• 206010002906 aortic stenosis Diseases 0.000 description 1
• 201000006800 aortic valve disease 1 Diseases 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
• 230000010516 arginylation Effects 0.000 description 1
• 108010062796 arginyllysine Proteins 0.000 description 1
• 208000011775 arteriosclerosis disease Diseases 0.000 description 1
• 210000004507 artificial chromosome Anatomy 0.000 description 1
• 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• 230000003143 atherosclerotic effect Effects 0.000 description 1
• 208000013914 atrial heart septal defect Diseases 0.000 description 1
• 206010003664 atrial septal defect Diseases 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
• 208000009361 bacterial endocarditis Diseases 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 210000004227 basal ganglia Anatomy 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 208000021654 bicuspid aortic valve disease Diseases 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 239000003833 bile salt Substances 0.000 description 1
• 229940093761 bile salts Drugs 0.000 description 1
• 210000003445 biliary tract Anatomy 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 208000006752 brain edema Diseases 0.000 description 1
• 201000005308 brain ependymoma Diseases 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 201000010135 brain oligodendroglioma Diseases 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 201000008275 breast carcinoma Diseases 0.000 description 1
• 201000005389 breast carcinoma in situ Diseases 0.000 description 1
• 201000009267 bronchiectasis Diseases 0.000 description 1
• 201000003848 bronchiolitis obliterans Diseases 0.000 description 1
• 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 description 1
• 206010006451 bronchitis Diseases 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 208000000594 bullous pemphigoid Diseases 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 230000011496 cAMP-mediated signaling Effects 0.000 description 1
• BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
• 229960004015 calcitonin Drugs 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 229910001424 calcium ion Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 230000003185 calcium uptake Effects 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 210000003710 cerebral cortex Anatomy 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 230000035605 chemotaxis Effects 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 201000005353 childhood germ cell brain tumor Diseases 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 231100000359 cholestasis Toxicity 0.000 description 1
• 230000007870 cholestasis Effects 0.000 description 1
• 201000004735 chromophil adenoma of the kidney Diseases 0.000 description 1
• 230000008711 chromosomal rearrangement Effects 0.000 description 1
• 238000003200 chromosome mapping Methods 0.000 description 1
• 208000007451 chronic bronchitis Diseases 0.000 description 1
• 208000030373 chronic endometritis Diseases 0.000 description 1
• 208000024207 chronic leukemia Diseases 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 description 1
• 201000006368 chronic pyelonephritis Diseases 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 208000008609 collagenous colitis Diseases 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 239000000084 colloidal system Substances 0.000 description 1
• 230000004732 colorectal carcinogenesis Effects 0.000 description 1
• 201000010989 colorectal carcinoma Diseases 0.000 description 1
• 208000016576 colorectal neuroendocrine tumor G1 Diseases 0.000 description 1
• 230000024203 complement activation Effects 0.000 description 1
• 230000009918 complex formation Effects 0.000 description 1
• 238000013329 compounding Methods 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 208000028831 congenital heart disease Diseases 0.000 description 1
• 108091036078 conserved sequence Proteins 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 201000009805 cryptogenic organizing pneumonia Diseases 0.000 description 1
• 201000000160 cryptorchidism Diseases 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
• 208000012106 cystic neoplasm Diseases 0.000 description 1
• 229960003067 cystine Drugs 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 230000017858 demethylation Effects 0.000 description 1
• 238000010520 demethylation reaction Methods 0.000 description 1
• 230000003210 demyelinating effect Effects 0.000 description 1
• 239000003398 denaturant Substances 0.000 description 1
• 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 210000004207 dermis Anatomy 0.000 description 1
• 230000001496 desquamative effect Effects 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 150000001982 diacylglycerols Chemical class 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 102000004419 dihydrofolate reductase Human genes 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• 231100000676 disease causative agent Toxicity 0.000 description 1
• 238000002224 dissection Methods 0.000 description 1
• 201000008243 diversion colitis Diseases 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
• 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
• 208000001848 dysentery Diseases 0.000 description 1
• 208000002296 eclampsia Diseases 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 201000009372 encapsulated thymoma Diseases 0.000 description 1
• 201000002491 encephalomyelitis Diseases 0.000 description 1
• 208000001991 endodermal sinus tumor Diseases 0.000 description 1
• 201000003914 endometrial carcinoma Diseases 0.000 description 1
• 208000011099 endometrial disease Diseases 0.000 description 1
• 201000006828 endometrial hyperplasia Diseases 0.000 description 1
• 208000016018 endometrial polyp Diseases 0.000 description 1
• 201000009274 endometriosis of uterus Diseases 0.000 description 1
• 210000004696 endometrium Anatomy 0.000 description 1
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
• 230000008694 endothelial dysfunction Effects 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 210000003989 endothelium vascular Anatomy 0.000 description 1
• 238000003366 endpoint assay Methods 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 208000017338 epidermoid cysts Diseases 0.000 description 1
• 210000000918 epididymis Anatomy 0.000 description 1
• 201000000165 epidural abscess Diseases 0.000 description 1
• 208000037888 epithelial cell injury Diseases 0.000 description 1
• 230000000925 erythroid effect Effects 0.000 description 1
• 230000010437 erythropoiesis Effects 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 210000003020 exocrine pancreas Anatomy 0.000 description 1
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
• JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
• 208000027869 fibroepithelial polyp Diseases 0.000 description 1
• 206010016629 fibroma Diseases 0.000 description 1
• 230000004992 fission Effects 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
• 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 1
• 229940014144 folate Drugs 0.000 description 1
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 230000022244 formylation Effects 0.000 description 1
• 238000006170 formylation reaction Methods 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
• 201000000052 gastrinoma Diseases 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 230000004545 gene duplication Effects 0.000 description 1
• 230000007614 genetic variation Effects 0.000 description 1
• 238000003205 genotyping method Methods 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 230000007387 gliosis Effects 0.000 description 1
• 201000005626 glomangioma Diseases 0.000 description 1
• 210000003904 glomerular cell Anatomy 0.000 description 1
• 231100000852 glomerular disease Toxicity 0.000 description 1
• 231100000853 glomerular lesion Toxicity 0.000 description 1
• 208000008605 glucosephosphate dehydrogenase deficiency Diseases 0.000 description 1
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 230000001279 glycosylating effect Effects 0.000 description 1
• 201000003872 goiter Diseases 0.000 description 1
• 208000001786 gonorrhea Diseases 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
• 201000000079 gynecomastia Diseases 0.000 description 1
• 150000003278 haem Chemical group 0.000 description 1
• 210000003780 hair follicle Anatomy 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
• 208000024348 heart neoplasm Diseases 0.000 description 1
• 208000025339 heart septal defect Diseases 0.000 description 1
• 208000018578 heart valve disease Diseases 0.000 description 1
• 201000011066 hemangioma Diseases 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 230000000004 hemodynamic effect Effects 0.000 description 1
• 230000002949 hemolytic effect Effects 0.000 description 1
• 201000002303 hemopericardium Diseases 0.000 description 1
• 210000002767 hepatic artery Anatomy 0.000 description 1
• 231100000753 hepatic injury Toxicity 0.000 description 1
• 210000002989 hepatic vein Anatomy 0.000 description 1
• 208000005252 hepatitis A Diseases 0.000 description 1
• 208000009601 hereditary spherocytosis Diseases 0.000 description 1
• 238000012188 high-throughput screening assay Methods 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 201000000284 histiocytoma Diseases 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 235000001050 hortel pimenta Nutrition 0.000 description 1
• 210000004754 hybrid cell Anatomy 0.000 description 1
• 208000003906 hydrocephalus Diseases 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
• 238000002169 hydrotherapy Methods 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
• 230000000148 hypercalcaemia Effects 0.000 description 1
• 208000030915 hypercalcemia disease Diseases 0.000 description 1
• 201000001421 hyperglycemia Diseases 0.000 description 1
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
• 201000009939 hypertensive encephalopathy Diseases 0.000 description 1
• 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
• 230000002218 hypoglycaemic effect Effects 0.000 description 1
• 230000036543 hypotension Effects 0.000 description 1
• 208000003532 hypothyroidism Diseases 0.000 description 1
• 230000002989 hypothyroidism Effects 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 206010021198 ichthyosis Diseases 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 230000003053 immunization Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 230000007813 immunodeficiency Effects 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 208000033065 inborn errors of immunity Diseases 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 201000006747 infectious mononucleosis Diseases 0.000 description 1
• 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
• 206010022498 insulinoma Diseases 0.000 description 1
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 208000037817 intestinal injury Diseases 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 201000009941 intracranial hypertension Diseases 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
• 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
• 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
• 230000026045 iodination Effects 0.000 description 1
• 238000006192 iodination reaction Methods 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 1
• 210000001117 keloid Anatomy 0.000 description 1
• 210000000244 kidney pelvis Anatomy 0.000 description 1
• 229940116108 lactase Drugs 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• 201000010260 leiomyoma Diseases 0.000 description 1
• 206010024217 lentigo Diseases 0.000 description 1
• 206010024378 leukocytosis Diseases 0.000 description 1
• 208000036546 leukodystrophy Diseases 0.000 description 1
• 201000002364 leukopenia Diseases 0.000 description 1
• 231100001022 leukopenia Toxicity 0.000 description 1
• 201000011486 lichen planus Diseases 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 238000004811 liquid chromatography Methods 0.000 description 1
• 208000007903 liver failure Diseases 0.000 description 1
• 231100000835 liver failure Toxicity 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 201000011059 lobular neoplasia Diseases 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
• 208000016992 lung adenocarcinoma in situ Diseases 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 230000029849 luteinization Effects 0.000 description 1
• 206010025226 lymphangitis Diseases 0.000 description 1
• 208000002502 lymphedema Diseases 0.000 description 1
• 208000004341 lymphocytic colitis Diseases 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 210000005004 lymphoid follicle Anatomy 0.000 description 1
• 208000019420 lymphoid neoplasm Diseases 0.000 description 1
• 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
• 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 201000000564 macroglobulinemia Diseases 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• 230000036244 malformation Effects 0.000 description 1
• 201000005857 malignant hypertension Diseases 0.000 description 1
• 208000006178 malignant mesothelioma Diseases 0.000 description 1
• 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
• 208000027202 mammary Paget disease Diseases 0.000 description 1
• 201000007261 marantic endocarditis Diseases 0.000 description 1
• 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
• 208000021937 marginal zone lymphoma Diseases 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 208000008585 mastocytosis Diseases 0.000 description 1
• 230000013011 mating Effects 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 210000002954 meckel diverticulum Anatomy 0.000 description 1
• 208000009242 medullary sponge kidney Diseases 0.000 description 1
• 231100001016 megaloblastic anemia Toxicity 0.000 description 1
• 210000002752 melanocyte Anatomy 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 230000028161 membrane depolarization Effects 0.000 description 1
• 231100000855 membranous nephropathy Toxicity 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 201000008806 mesenchymal cell neoplasm Diseases 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 230000003458 metachromatic effect Effects 0.000 description 1
• 230000015689 metaplastic ossification Effects 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 150000002741 methionine derivatives Chemical class 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 206010063344 microscopic polyangiitis Diseases 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 210000004115 mitral valve Anatomy 0.000 description 1
• 201000010225 mixed cell type cancer Diseases 0.000 description 1
• 208000029638 mixed neoplasm Diseases 0.000 description 1
• 208000008588 molluscum contagiosum Diseases 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 210000003003 monocyte-macrophage precursor cell Anatomy 0.000 description 1
• 210000000472 morula Anatomy 0.000 description 1
• 210000002161 motor neuron Anatomy 0.000 description 1
• 208000005264 motor neuron disease Diseases 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 229940051866 mouthwash Drugs 0.000 description 1
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
• 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 208000029200 multiple sclerosis variant Diseases 0.000 description 1
• 208000010805 mumps infectious disease Diseases 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 210000001167 myeloblast Anatomy 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 208000003786 myxedema Diseases 0.000 description 1
• ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 239000006218 nasal suppository Substances 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 208000012108 neoplastic polyp Diseases 0.000 description 1
• 201000000173 nephrocalcinosis Diseases 0.000 description 1
• 208000023833 nerve sheath neoplasm Diseases 0.000 description 1
• 201000010193 neural tube defect Diseases 0.000 description 1
• 208000007538 neurilemmoma Diseases 0.000 description 1
• 208000022145 neurocutaneous syndrome Diseases 0.000 description 1
• 201000011519 neuroendocrine tumor Diseases 0.000 description 1
• 208000002761 neurofibromatosis 2 Diseases 0.000 description 1
• 208000022032 neurofibromatosis type 2 Diseases 0.000 description 1
• 208000029974 neurofibrosarcoma Diseases 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 208000014500 neuronal tumor Diseases 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 208000002040 neurosyphilis Diseases 0.000 description 1
• 208000004649 neutrophil actin dysfunction Diseases 0.000 description 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
• 208000016135 nonbacterial thrombotic endocarditis Diseases 0.000 description 1
• 230000002560 nonimmunologic effect Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 210000003924 normoblast Anatomy 0.000 description 1
• 239000002853 nucleic acid probe Substances 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 230000000414 obstructive effect Effects 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
• 229940127234 oral contraceptive Drugs 0.000 description 1
• 239000003539 oral contraceptive agent Substances 0.000 description 1
• 201000005737 orchitis Diseases 0.000 description 1
• 208000012221 ovarian Sertoli-Leydig cell tumor Diseases 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 230000027758 ovulation cycle Effects 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 206010033675 panniculitis Diseases 0.000 description 1
• 244000045947 parasite Species 0.000 description 1
• 239000000199 parathyroid hormone Substances 0.000 description 1
• 229960001319 parathyroid hormone Drugs 0.000 description 1
• 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 208000003278 patent ductus arteriosus Diseases 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 230000009984 peri-natal effect Effects 0.000 description 1
• 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
• 210000000578 peripheral nerve Anatomy 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 238000011170 pharmaceutical development Methods 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 208000001297 phlebitis Diseases 0.000 description 1
• 229940080469 phosphocellulose Drugs 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 238000005222 photoaffinity labeling Methods 0.000 description 1
• 108091008695 photoreceptors Proteins 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 230000006461 physiological response Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 230000019612 pigmentation Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 208000010626 plasma cell neoplasm Diseases 0.000 description 1
• 210000004180 plasmocyte Anatomy 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 210000004224 pleura Anatomy 0.000 description 1
• 201000003437 pleural cancer Diseases 0.000 description 1
• 206010035653 pneumoconiosis Diseases 0.000 description 1
• 201000003144 pneumothorax Diseases 0.000 description 1
• 230000010287 polarization Effects 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 239000008389 polyethoxylated castor oil Substances 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 208000007232 portal hypertension Diseases 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 201000011461 pre-eclampsia Diseases 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 230000013823 prenylation Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
• 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
• 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 208000035803 proliferative type breast fibrocystic change Diseases 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 210000004129 prosencephalon Anatomy 0.000 description 1
• 230000004845 protein aggregation Effects 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 230000009145 protein modification Effects 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• 201000003489 pulmonary alveolar proteinosis Diseases 0.000 description 1
• 201000009732 pulmonary eosinophilia Diseases 0.000 description 1
• 201000003456 pulmonary hemosiderosis Diseases 0.000 description 1
• 208000002815 pulmonary hypertension Diseases 0.000 description 1
• 208000009138 pulmonary valve stenosis Diseases 0.000 description 1
• 208000030390 pulmonic stenosis Diseases 0.000 description 1
• 229940043131 pyroglutamate Drugs 0.000 description 1
• 230000006340 racemization Effects 0.000 description 1
• 239000012857 radioactive material Substances 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000001373 regressive effect Effects 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
• 206010038433 renal dysplasia Diseases 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• 208000004124 rheumatic heart disease Diseases 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 201000004409 schistosomiasis Diseases 0.000 description 1
• 206010039667 schwannoma Diseases 0.000 description 1
• 201000008662 sclerosing adenosis of breast Diseases 0.000 description 1
• 208000010157 sclerosing cholangitis Diseases 0.000 description 1
• 238000007423 screening assay Methods 0.000 description 1
• 201000003385 seborrheic keratosis Diseases 0.000 description 1
• 208000011581 secondary neoplasm Diseases 0.000 description 1
• 210000000582 semen Anatomy 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
• 231100000004 severe toxicity Toxicity 0.000 description 1
• 239000013605 shuttle vector Substances 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 201000000195 skin tag Diseases 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
• 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 208000014653 solitary fibrous tumor Diseases 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 208000002320 spinal muscular atrophy Diseases 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 230000036262 stenosis Effects 0.000 description 1
• 208000037804 stenosis Diseases 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 230000004960 subcellular localization Effects 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 208000035581 susceptibility to neural tube defects Diseases 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 208000001608 teratocarcinoma Diseases 0.000 description 1
• 201000002814 testicular lymphoma Diseases 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 229940126585 therapeutic drug Drugs 0.000 description 1
• 235000019157 thiamine Nutrition 0.000 description 1
• KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
• 229960003495 thiamine Drugs 0.000 description 1
• 239000011721 thiamine Substances 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 230000003582 thrombocytopenic effect Effects 0.000 description 1
• 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000005026 transcription initiation Effects 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000002463 transducing effect Effects 0.000 description 1
• 230000017105 transposition Effects 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 208000007340 tricuspid atresia Diseases 0.000 description 1
• 206010044697 tropical sprue Diseases 0.000 description 1
• 201000002311 trypanosomiasis Diseases 0.000 description 1
• 239000002753 trypsin inhibitor Substances 0.000 description 1
• 208000009999 tuberous sclerosis Diseases 0.000 description 1
• 201000007423 tubular adenocarcinoma Diseases 0.000 description 1
• 210000005239 tubule Anatomy 0.000 description 1
• 230000005951 type IV hypersensitivity Effects 0.000 description 1
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
• 201000008297 typhoid fever Diseases 0.000 description 1
• HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
• ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
• 230000009452 underexpressoin Effects 0.000 description 1
• 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 208000019206 urinary tract infection Diseases 0.000 description 1
• 208000008281 urolithiasis Diseases 0.000 description 1
• 206010046811 uterine polyp Diseases 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 238000009777 vacuum freeze-drying Methods 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 208000027185 varicose disease Diseases 0.000 description 1
• 201000011531 vascular cancer Diseases 0.000 description 1
• 210000005167 vascular cell Anatomy 0.000 description 1
• 208000026875 vascular ectasia Diseases 0.000 description 1
• 206010055031 vascular neoplasm Diseases 0.000 description 1
• 230000000982 vasogenic effect Effects 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 210000001631 vena cava inferior Anatomy 0.000 description 1
• 210000002620 vena cava superior Anatomy 0.000 description 1
• 230000002861 ventricular Effects 0.000 description 1
• 201000002498 viral encephalitis Diseases 0.000 description 1
• 230000029812 viral genome replication Effects 0.000 description 1
• 208000002670 vitamin B12 deficiency Diseases 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 238000001086 yeast two-hybrid system Methods 0.000 description 1